USFDA-hit Indian pharma looks for whistleblowers
- Purnia rally: Modi takes a dig at Nitish, says his PM dream was reason for break up of alliance
- Still no sign of Malaysia Airlines jet lost in "unprecedented mystery"
- Raj Thackeray warms up to Narendra Modi, lets Sena feel the heat
- Uttar Pradesh BJP wants tickets for four riot-accused MLAs
- Haryana, Gujarat top industry-friendly states, Maharashtra among bottom five
Gurgaon-based Ranbaxy Laboratories' troubles began when Dinesh Thakur, who had served on the board of the drug firm between 2003 and 2005, approached the US Food and Drug Administration and department of justice with proof that the company had indulged in data tampering, supply of falsified data to the regulator and production and sale of substandard drugs. It now turns out that one reason why Thakur chose to invoke the US' robust whistleblower policy (which forced Ranbaxy to cough up $500 million) rather than first take up the matter with the company's top management was that the company then lacked a whistleblower policy.
Clause 49 of the listing agreement with the Securities and Exchange Board of India (Sebi) mandates disclosure of whether an entity has a whistleblower policy or not. However, Indian laws do not make it binding for a company adopt such a policy.
While some Indian pharma companies have adopted whistleblower policies, others, including some top-notch firms, haven't. Lupin, Dr Reddy's Laboratories, Wockhardt and Piramal Enterprises have defined their whistleblower policies, according to responses received from the companies to FE queries and disclosures in their annual reports. Lupin and Dr Reddy's have even constituted an internal mechanism to handle such complaints.
A Lupin spokesperson said: "Our top management itself is responsible for (the policy) and any such incidents get reported directly to an email box called firstname.lastname@example.org. A copy of the mails go to the vice-chairman, managing director and CFO of the company, so people have access to the very top tiers of the company (and) if they want to talk about anything they can do so fearlessly."
Dr Reddy's said: "We have a robust whistleblower policy. The chief ombudsperson is internal." Mumbai-based Sun Pharmaceuticals, India's largest pharmaceutical company by revenue, said it is in the process of implementing a whistleblower policy.
- Bengal model better than Modi’s Gujarat, says Didi
- Sindhis threaten to move HC if Sindhu Sagar not cleaned
- Three RTI activists whom Kejriwal paid homage are alive
- Poojary wins Mangalore primary
- Short change: Health cover for girl child at 50% discount
- Run with the bulls, don’t lose out to foreign investors again
- AAP workers stage protest outside Kejriwal’s residence over ticket distribution
- BJP boycotts NDTV over news gaffe | The Indian Express
- Out of the promised 50,000 homes for the poor, not even 50 constructed in Gujarat by BJP: Kejriwal
- BJP complains to EC against Rahul over RSS remarks, seeks derecognition of Congress